MYGN

Business Context and Reporting Period

Company: Myriad Genetics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2002
Overview: Myriad is a biopharmaceutical company focused on developing therapeutic and predictive medicine products using proprietary proteomic technologies. Operations are divided into two segments: Myriad Pharmaceuticals (therapeutic drug discovery) and Myriad Genetic Laboratories (predictive medicine testing). The company has not yet attained profitability and relies on research collaborations and predictive medicine sales for revenue.

Key Financial Metrics

Note: The filing text does not provide a specific debt figure; the company reported no interest expense for the period, indicating minimal or no interest-bearing debt.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 19% year-over-year, driven primarily by a 57% surge in predictive medicine revenue ($26.8M vs $17.1M). This growth was attributed to increased sales of existing products and the launch of two new tests (COLARIS AP and MELARIS).
• Research Revenue Decline: Research revenue decreased 4% to $27.0M, largely due to the completion of major collaborations with Bayer and TMRI in late 2001, partially offset by new agreements with Abbott and DuPont.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 49% to $25.5M due to the expansion of the sales force from 75 to 106 representatives and direct-to-consumer marketing campaigns. R&D expenses increased 7% to $36.3M, driven by clinical trials for Flurizan and internal drug discovery.
• Liquidity: Cash and marketable securities decreased by $21.7 million (15%) due to increased operational expenditures and lower interest income resulting from declining interest rates.

Guidance, Outlook, and Risks

Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and facility growth. The company anticipates having sufficient capital resources to fund operations for at least the next two years.

Key Developments:

• Therapeutics: Flurizan (prostate cancer) is in a large multi-center human clinical trial. An IND application was submitted for MPC-7869 (Alzheimer's disease). Fifteen drug candidates are in pre-clinical testing.
• Predictive Medicine: Five products are commercialized (BRACAnalysis, COLARIS, COLARIS AP, MELARIS, CardiaRisk). International marketing collaborations exist in Austria, Brazil, Canada, Germany, Japan, and Switzerland.

Risks and Contingencies:

• Profitability: No assurance that the company will ever achieve profitability.
• Regulatory: Therapeutic products require FDA approval; predictive medicine products are subject to CLIA regulations. Delays or denials could materially harm the business.
• Collaboration Dependence: Future revenue depends on maintaining strategic alliances with 12 major pharmaceutical partners. Termination of these agreements would be detrimental.
• Intellectual Property: Risks regarding patent infringement claims and the ability to protect proprietary technologies.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $124.2M cash position against the projected $16.3M annual operating cash outflow and capital expenditure needs.
• Reimbursement Status: Confirm insurance coverage rates for predictive medicine products, specifically noting that CardiaRisk is currently not reimbursed by health insurance.
• Clinical Trial Progress: Monitor the results of the Flurizan Phase II/III trials and the status of the MPC-7869 IND application for Alzheimer's.
• Collaboration Renewals: Assess the status of expiring research agreements and the potential for new milestone payments or royalties.
• Patent Portfolio: Review the status of the 99 issued patents and pending applications, particularly regarding BRACAnalysis and COLARIS, to ensure protection against competitors.